Free Trial
→ $30 stock to buy before Starlink goes public (WATCH NOW!) (From Paradigm Press) (Ad)tc pixel
LON:TCF

Theracryf Final Earnings Report

GBX 0.22 0.00 (-0.89%)
As of 07:18 AM Eastern
ProfileEarnings History

Theracryf EPS Results

Actual EPS
-GBX 0.36
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Theracryf Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Theracryf Announcement Details

Quarter
Final
Date
6/3/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Theracryf Earnings Headlines

TheraCryf appoints new board member, issues options
May 2, 2025  |  uk.investing.comhttps://uk.investing.com/news/company-news/theracryf-appoints-new-board-member-issues-options-93CH-4058518
Theracryf Plc (TCF.L)
January 18, 2025  |  ca.finance.yahoo.comhttps://ca.finance.yahoo.com/quote/TCF.L/hiring-trends/
Goldman Sachs just told you what to buy (most people missed it)
Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - not chips, not funding, but power. Demand is growing 15% per year and the grid can't keep up. One small company makes the exact equipment these data centers need. They're sitting on $1.5 billion in orders, their hardware is already inside Musk's Colossus, and the stock still trades like a name nobody's heard of. Analyst Dylan Jovine is releasing the ticker for free.tc pixel
June 5 at 1:00 AM  |  Behind the Markets (Ad)
Theracryf PLC Share Chat (TCF)
January 13, 2025  |  lse.co.ukhttps://www.lse.co.uk/ShareChat.html?ShareTicker=TCF&thread=D6EDFB9D-E83F-43D6-8E6C-4DBC80FD8FDF
See More Theracryf Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Theracryf? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Theracryf and other key companies, straight to your email.

About Theracryf

Theracryf (LON:TCF) is a biotechnology company developing new medicines for addiction and other disorders of the brain, areas of significant unmet medical need within central nervous system (CNS) disorders. The Group’s lead programme is a novel, best-in-class orexin-1 receptor antagonist being developed as a potential treatment for addiction, including binge eating, alcohol and other substance use disorders. The programme is heavily de-risked, demonstrates superior selectivity and high receptor occupancy, and is fully funded through to clinical readiness, with regulatory submissions targeted for 2026. TheraCryf also has a dopamine transporter (DAT) modulator programme addressing fatigue of brain origin, including fatigue associated with multiple sclerosis, chemotherapy and narcolepsy. The Group also has a legacy, grant-funded, oncology programme in glioblastoma with SFX-01. TheraCryf operates a capital-light, virtual development model advancing programmes to early clinical or proof-of-concept stage before partnering with larger pharmaceutical or biotechnology companies.

View Theracryf Profile
Earnings Tools